The Effect of Jazar Supplement on Quality of Life and Sexual Function in Postmenopausal Women: A Double-Blind, Randomized, Placebo-Controlled Trial

Table 2

A summary of changes in the scores of the MENQOL subscales during the trial period.

Subscales	Measurement points	Jazar (n = 43)	Placebo (n = 41)	value
Vasomotor	Baseline	3.46 ± 1.59	3.21 ± 1.34	0.433
	Week 4	2.24 ± 1.27	3.24 ± 1.29	0.001
	Week 8	1.61 ± 1.20	2.76 ± 1.14	<0.001
	Week 10	1.59 ± 1.20	2.62 ± 1.42	0.001
Psychosocial	Baseline	2.58 ± 1.49	2.18 ± 1.17	0.177
	Week 4	2.23 ± 1.29	3.18 ± 1.21	0.001
	Week 8	2.04 ± 1.24	2.49 ± 1.07	0.079
	Week 10	2.03 ± 1.25	1.24 ± 2.69	0.017
Physical	Baseline	2.79 ± 1.18	2.42 ± 1.29	0.178
	Week 4	2.47 ± 1.12	3.42 ± 1.07	<0.001
	Week 8	2.29 ± 1.08	2.69 ± 1.17	0.109
	Week 10	2.28 ± 1.09	2.92 ± 1.09	0.009
Sexual	Baseline	4.03 ± 1.57	3.66 ± 1.77	0.311
	Week 4	3.37 ± 1.56	4.30 ± 1.41	0.005
	Week 8	3.04 ± 1.39	3.71 ± 1.46	0.033
	Week 10	3.01 ± 1.38	3.75 ± 1.44	0.020
Total	Baseline	3.22 ± 0.99	2.87 ± 0.98	0.108
	Week 4	2.58 ± 0.87	3.53 ± 0.79	<0.001
	Week 8	2.24 ± 0.88	2.91 ± 0.78	<0.001
	Week 10	2.23 ± 0.88	2.99 ± 0.88	<0.001

The data are presented as mean (standard deviation). For comparison of the groups, an independent t-test was used.